葸环类药物在乳腺癌治疗中的新进展
摘要
过去30年,蒽环类药物广泛用于乳腺癌的治疗,早期乳腺癌研究协作组所做的meta分析更是确定了其价值。然而最近一些研究发现蒽环类对于HER2基因扩增以及TOP2A变异的患者更有效,
出处
《医学临床研究》
CAS
2010年第8期1486-1489,共4页
Journal of Clinical Research
参考文献33
-
1Clarke M, Collins R, Darby S, a al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet , 2005,366 (9503) : 2087- 2106.
-
2Pritehard KI, Shepherd LE, O'Malley FP, et al . HER2 and responsiveness of breast cancer to adjuvant chemotherapy[J]. N Engl J Med ,2006,354(20) :2103-2111.
-
3O'Malley FP, Chia S, Tu D, et al . Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy [J]. J Natl Cancer lnst ,2009,101(9):644-650.
-
4Orlando L, Del Curto B, Gandini S, et al . Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracyeline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer [J]. Breast ,2008,17(5) :506-511.
-
5Tanner M, Isola J, Wiklund T, et al. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandi- navian Breast Group Trial 9401[J].J Clin Oncol , 2006,24 (16) :2428-2436.
-
6Tubbs R, Barlow WE, Budd GT, et al . Outcome of patients with early-stage breast eaneer treated with doxorubiein-based adjuvant chemotherapy as a funetion of HER2 and TOP2A status[J]. J Clin Oncol ,2009,27(24) :3881-3886.
-
7Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients[J], j Natl Cancer lnst, 2008, 100 (15) :1058-1067.
-
8Doyle JJ, Neugut AI, Jaeobson JS, et al . Chemotherapy and cardiotoxicity in older breast cancer patients: a population- based study[J]. J Clin Oncol , 2005,23 (34) : 8597-8605.
-
9Sng JH. Molecular cloning and characterization of the human topoisomerase II alpha and II beta genes: Evidence for isoform evolution through gene duplication[J]. Biochim Biophys Acta ,1999,1444(3) :395-406.
-
10Kellner U, Sehested M, Jensen PB, et al . Culprit and victim -DNA topoisomerase II [J].Lancet Oncol , 2002,3 (4) : 235- 243.
二级参考文献18
-
1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
-
2Bozionellou V,Mavroudis D,Perraki M,et al.Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone and bone marrow of patients with breast cancer[J].Clin Cancer Res,2004,10(24):8185-8194.
-
3Bozzetti C,Nizzoli R,Guazzi A,et al.HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer[J].Ann Oncol,2002,13(9):1398-1403.
-
4Press MF,Sauter G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials[J].Clin Cancer Res,2005,11(18):6598-6607.
-
5Vogel CL,Reddy JC,Reyno LM.Efficacy of trastuzumab[J].Cancer Res,2005,65(5):2044.
-
6Slamon DJ,Romond EH,Perez EA.Advances in adjuvant therapy for breast cancer[J].Clin Adv Hematol Oncol,2006,4(3):suppl 1,4-9.
-
7Nabhohtz JM,Slamon n New adjuvant strategies for breast cancer:meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)[J].Semin Oncol,2001,28(1 Suppl 3):1-12.
-
8Lan C,Liu JM,Liu TW,et al.erbB2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis[J].Am J Clin Pathol,2005,124(1):97-102.
-
9Dolan M,Snover D.Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice[J].Am J Clin Pathol,2005,123(5):766-770.
-
10Gupta D, Middleton L P,Whitaker M J, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer[J]. Am J Clin Pathol, 2003,119: 381-387.
共引文献21
-
1谢敏,刘敬义,韩涛.荧光原位杂交检测乳腺癌中Her-2基因的可行性研究[J].求医问药(下半月),2013(9):30-31.
-
2吕亚莉,钟梅,刘琳,韦立新,赵坡.乳腺癌17号染色体多体的临床病理意义[J].中华病理学杂志,2008,37(2):88-91. 被引量:6
-
3吕亚莉,钟梅,刘琳,赵坡.335例乳腺癌HER-2基因扩增及17号染色体多体的临床病理学分析[J].诊断病理学杂志,2008,15(3):169-173. 被引量:16
-
4高艳伟,高维实,赖玉书,武晋,张海霞.Her-2与乳腺癌研究进展[J].内蒙古医学院学报,2008,30(1):69-72. 被引量:6
-
5李凌云,卢海蓉,易俊波,林枫.HER-2/neu基因探针的制备及特异性分析[J].医学分子生物学杂志,2008,5(5):393-398.
-
6连婧,王全红,李丽,王跃华,白玮.IHC、FISH与CISH检测乳腺癌HER2基因状态的对比研究[J].肿瘤研究与临床,2008,20(12):816-819. 被引量:9
-
7王强,曾健.原癌基因HER2/neu在乳腺癌中的表达及研究进展[J].广西医学,2009,31(6):868-871. 被引量:1
-
8江峰,倪灿荣.发色原位杂交技术对乳腺癌HER2基因检测的改进[J].中国慢性病预防与控制,2010,18(3):294-295.
-
9杨静,田卫华,任大宏,冯家成.荧光原位杂交与免疫组织化学技术检测乳腺癌中Her-2基因扩增及蛋白表达的比较[J].国际肿瘤学杂志,2010,37(10):799-800.
-
10杨静,田卫华,任大宏,冯家成.荧光原位杂交检测浸润性乳腺癌中人类表皮生长因子受体2基因临床应用的可行性研究[J].实用医技杂志,2011,18(2):129-131.
-
1吴培平,杨静.支气管占位误诊1例[J].西南国防医药,2012,22(12):1283-1283.
-
2朱海涛.平阳霉素碘油乳剂治疗症状性子宫肌瘤的临床应用[J].中国临床实用医学,2008,2(5):65-66.
-
3周建宇,毛立民,王巍,吕少华,赵晶.MS-275联合平阳霉素对Tca-8113细胞生长和凋亡的影响[J].现代生物医学进展,2014,14(33):6407-6410.
-
4闫慧明,贾彬,马剑方,韩曙光.阿霉素诱导胰腺癌BxPC-3细胞凋亡过程中p38MAPK的表达[J].中国药物与临床,2005,5(11):809-811. 被引量:1
-
5夏月琴,何续逊.国产去甲长春花碱联合顺铂治疗蒽环类药物耐药乳腺癌23例临床观察[J].肿瘤防治杂志,2003,10(12):1284-1286.
-
6杨岳珍,陈琳.平阳霉素导致皮肤过敏反应2例[J].中华综合临床医学杂志(北京),2006,8(3):75-75.
-
7韩锦华,王彤,孙加强,臧洪瑞,白春江,李东波.鼻腔鼻窦内翻性乳头状瘤的综合治疗及预防复发的效果[J].中国耳鼻咽喉头颈外科,2008,15(11):640-642. 被引量:1
-
8刘文中,刘彩,刘正萍,李连英.瘤内注射平阳霉素治疗脉管瘤[J].中国耳鼻咽喉头颈外科,2007,14(2):77-78. 被引量:8
-
9王江云,陈勇,卢伟,韦传军.原发性肝癌经动脉化疗栓塞预防性应用抗生素前瞻性研究[J].第一军医大学学报,2005,25(6):757-758. 被引量:7
-
10刘文中,刘彩,刘慧光.平阳霉素治疗脉管瘤的副作用及其预防[J].中国耳鼻咽喉头颈外科,2009,16(6):296-298. 被引量:1